MARKET

ARVN

ARVN

Arvinas
NASDAQ
6.51
+0.04
+0.62%
After Hours: 6.55 +0.04 +0.61% 19:33 05/23 EDT
OPEN
6.30
PREV CLOSE
6.47
HIGH
6.56
LOW
6.29
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
37.38
52 WEEK LOW
5.90
MARKET CAP
475.17M
P/E (TTM)
-9.8786
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARVN last week (0512-0516)?
Weekly Report · 5d ago
Arvinas Is Maintained at Buy by UBS
Dow Jones · 05/15 13:54
Arvinas Price Target Cut to $21.00/Share From $74.00 by UBS
Dow Jones · 05/15 13:54
UBS Maintains Buy on Arvinas, Lowers Price Target to $21
Benzinga · 05/15 13:44
ARVINAS INC <ARVN.O>: UBS CUTS TARGET PRICE TO $21 FROM $74
Reuters · 05/15 12:38
Arvinas price target lowered to $21 from $74 at UBS
TipRanks · 05/15 09:55
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, UnitedHealth, Wells Fargo
Reuters · 05/15 07:41
Bank of America Securities Sticks to Its Buy Rating for Arvinas Holding Company (ARVN)
TipRanks · 05/15 02:06
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.